Shots:
- Biond to receive $125M up front in cash and will be eligible to receive ~$1B+ as development, regulatory & commercial milestones, along with royalties on sales of the therapy
- Biond will lead P-Ia study of BND-22, assessing its safety & tolerability as a single agent and in combination with approved cancer therapies as well as exploring potential associations b/w BND-22 anti-tumor activity, select tumor and blood-based biomarkers. Sanofi will be further responsible for clinical development and commercialization of BND-22
- BND-22 is a humanized IgG4, antagonist Ab targeting ILT2 receptor in development for solid tumors. The first P-Ia study of BND-22 is anticipated to start by mid-2021
Click here to read full press release/ article | Ref: PRNewswire | Image: 20 Minutes
The post Sanofi Signs a License Agreement with Biond for BND-22 first appeared on PharmaShots.
